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A major population of mucosal memory CD4þ
T cells, coexpressing IL-18Ra and DR3, display
innate lymphocyte functionality
P Holmkvist1,2, K Roepstorff2, H Uronen-Hansson1, C Sande´n3, S Gudjonsson4, O Patschan4, O Grip5,
J Marsal6, A Schmidtchen7,8, L Hornum2, JS Erjefa¨lt3, K Håkansson2 and WW Agace1,9
Mucosal tissues contain large numbers of memory CD4þ Tcells that, through T-cell receptor-dependent interactions
with antigen-presenting cells, are believed to have a key role in barrier defense andmaintenance of tissue integrity. Here
we identify a major subset of memory CD4þ Tcells at barrier surfaces that coexpress interleukin-18 receptor alpha (IL-
18Ra) and death receptor-3 (DR3), and display innate lymphocyte functionality. The cytokines IL-15 or the DR3 ligand
tumor necrosis factor (TNF)-likecytokine1A (TL1a) inducedmemory IL-18RaþDR3þCD4þ Tcells toproduce interferon-c,
TNF-a, IL-6, IL-5, IL-13, granulocyte–macrophage colony-stimulating factor (GM-CSF), and IL-22 in the presence of
IL-12/IL-18. TL1a synergized with IL-15 to enhance this response, while suppressing IL-15-induced IL-10 production.
TL1a- and IL-15-mediated cytokine induction required the presence of IL-18, whereas induction of IL-5, IL-13, GM-CSF,
and IL-22 was IL-12 independent. IL-18RaþDR3þCD4þ T cells with similar functionality were present in human skin,
nasal polyps, and, in particular, the intestine, where in chronic inflammation they localized with IL-18-producing cells
in lymphoid aggregates. Collectively, these results suggest that human memory IL-18RaþDR3þ CD4þ T cells may
contribute to antigen-independent innate responses at barrier surfaces.
INTRODUCTION
Body surfaces including mucosal tissues and the skin are con-
tinually exposed to challenges from the external environment,
including resident commensal microorganisms as well as a
multitude of bacterial and viral pathogens that use these
tissues as portals of entry and infection.1–3 Maintenance of
barrier tissue homeostasis is critically dependent on the
immune system’s ability to respond appropriately to such
challenges, a breakdown in which can lead to chronic
inflammatory diseases including inflammatory bowel disease,
asthma, and allergy.4–6
Barrier tissues contain numerous subsets of innate and
adaptive immune cells that together contribute to maintain
tissue homeostasis, and also, when poorly controlled, to
detrimental inflammatory reactions. Adaptive immune res-
ponses at barrier surfaces take several days to weeks to develop
as naive CD4þ T-cell scan antigen-presenting cells (APCs) in
tissue draining lymph nodes in search of their cognate antigen,
clonally expand, and subsequently migrate as effector CD4þ
T cells to lymphoid follicles, providing help to B cells, or via the
circulation into peripheral tissues. Having entered barrier
tissues, activated CD4þ T cells can persist for long periods of
time as tissue-resident memory populations,7 where they,
through the production of proinflammatory and regulatory
cytokines, have key roles in regulating local immunity. The
activity of tissue-resident memory CD4þ T cell is primarily
believed to be regulated through T-cell receptor (TCR)-depen-
dent recognition of cognate antigen-major histocompatibility
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complex (MHC)-II on local APCs,8,9 however memory CD4þ
T cells can produce cytokines independently of TCR activation.
For example, IL-12 and IL-18 have been shown to induce TCR-
independent interferon-g (IFN-g) production in CD4þ
T cells10,11 and addition of either IL-1510 or the tumor necrosis
factor (TNF) family member, TNF-like cytokine 1A (TL1a)/
TNF super family member 15, can enhance this response.11–13
Whether IL-15 and TL1a can synergize to induce cytokine
production by CD4þ T cells, the identity of such cytokine-
responsive CD4þ T cells, and their potential presence at
human barrier tissues remains however unclear.
Here we identify interleukin-18 receptor alpha-positive
(IL-18Raþ ) death receptor-3 (DR3)þCD4þ T cells as a major
population of human memory CD4þ T cells with innate
lymphocyte functionality. Among memory CD4þ T cells,
IL-18RaþDR3þCD4þ T cells alone produced a wide range of
cytokines in response to IL-12/IL-18/IL-15 or IL-12/IL-18/
TL1a, and this response was significantly enhanced after the
addition of both TL1a and IL-15. We further demonstrate that
IL-18RaþDR3þCD4þ T cells with similar functionality are
present in large numbers in barrier tissues, in particular in the
intestinal mucosa, where they represented the majority of
tissue-resident CD4þ T cells. Taken together, our results
highlight a hitherto underappreciated innate activity of
memory CD4þ T cells in barrier tissues.
RESULTS
TL1aand IL-15synergize to induceproinflammatorycytokine
production in peripheral blood CD45ROþCD4þ T cells
To assess the impact of TL1a and IL-15 in regulating proinflam-
matory cytokine production in memory CD4þ T cells,
CD45ROþCD4þ T cells were purified from peripheral blood
(PB) of healthy donors and cultured with IL-12/IL-18 together
with IL-15, TL1a, or IL-15 andTL1a (Figure 1). Consistentwith
previous results,10,11 TL1a or IL-15 induced IFN-g production
in CD45ROþCD4þ T cells in the presence of IL-12/IL-18
(Figure 1a, b and Supplementary Figure S1A online). To
determinewhether TL1a and IL-15 synergize to promote IFN-g
responses, CD45ROþCD4þ T cells were incubated with
optimal concentrations of TL1a (100 ngml 1) together with
IL-15 (25 ngml 1) in the presence of IL-12/IL-18 (Figure 1a,
b). Addition of both TL1a and IL-15 induced a twofold increase
in the percentage of IFN-gþ cells and a threefold increase
in IFN-g secretion compared with either cytokine alone
(Figure 1a, b). TL1a induces the production of several proin-
flammatory cytokines in IL-12/IL-18-stimulated CD4þ T cells
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Figure1 Tumor necrosis factor-like cytokine 1A (TL1a)and interleukin-15 (IL-15) synergize to induceproinflammatory cytokine production inperipheral
bloodCD45ROþCD4þ T cells. Peripheral bloodCD45ROþCD4þ T cells (1 106 cellsml1, 200 ml per well) were cultured inmedium alone (control) or
with IL-12 (2 ngml1), IL-18 (50 ngml 1), IL-15 (25 ngml 1), and TL1a (100 ngml 1) as indicated. (a) Representative intracellular staining (top) and
percent (bottom row) of CD4þ T cells expressing interferon-g (IFN-g) 4 days after incubation with indicated cytokines or medium alone (control). Results
are themean (s.e.m.) of 10 biological replicates.Cells were pregated on live single cells. (b) Cytokine levels in culture supernatantswere assessed after 1
day (IFN-g) and 4 days (other cytokines). Results are the mean (s.e.m.) of 4 (IFN-g), 6 (IL-22), or 13 (other cytokines) biological replicates.
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includingGM-CSF, TNF-a, IL-6, and IL-13.13We thus assessed
whether IL-15 enhanced production of cytokines other than
IFN-g in the presence of IL-12/IL-18 and whether TL1a and
IL-15 synergized to promote expression of these cytokines
(Figure 1b). In IL-12/IL-18 cultures, both TL1a and IL-15 dose
dependently induced IL-6, TNF-a, GM-CSF, IL-5, IL-13, and
IL-22 expression in CD45ROþCD4þ T cells (Supple-
mentary Figure S1B) and addition of IL-15 (25 ngml 1)
together with optimal concentrations of TL1a (100 ngml 1)
induced a marked increase in all cytokines (Figure 1b). To
confirm that cytokine production by CD45ROþCD4þ T cells
occurred independently of cognate TCR–MHC-II interactions,
similar experiments were performed in the presence of
neutralizing MHC-II antibody (Supplementary Figure S2).
Addition of neutralizing MHC-II antibody had no effect on
cytokine induced cytokine production by CD45ROþCD4þ
T cells (Supplementary Figure S2A), despite its ability to
inhibit cell proliferation in a mixed lymphocyte reaction
(Supplementary Figure S2B). Previous studies have shown
that IL-12/IL-1814,15 and IL-12/IL-18/IL-15, but not anti-CD3-
mediated induction of IFN-g is p38 mitogen-activated protein
kinase dependent,10,14,15 and we found that TL1a- and IL-15-
induced proinflammatory cytokine production was p38 mito-
gen-activated protein kinase and phosphoinositide 3-kinase
dependent (Supplementary Figure S2C). Collectively, these
results indicate a marked synergy between TL1a and IL-15
in promoting proinflammatory cytokine production in
CD45ROþCD4þ T cells in the presence of IL-12/IL-18.
TL1a modulates cytokine expression through DR3
To determine whether the TL1a-mediated induction of pro-
inflammatory cytokines in CD4þ T cells was dependent on
DR3, CD45ROþCD4þ T cells were stimulated with IL-12/IL-
18/IL-15 in the presence/absence of TL1a together with a
neutralizing DR3 Fab0 or control Fab0 fragment (Supplemen-
tary Figure S3). Addition of neutralizing DR3 Fab0, but not
control Fab0, inhibited TL1a-mediated upregulation of all
proinflammatory cytokines, indicating that the proinflam-
matory effects of TL1a on CD45ROþCD4þ T cells are
mediated through DR3.
IL-15 and TL1a induction of proinflammatory cytokines
requires synergy with IL-18
To assess the role of IL-12 and IL-18 in TL1a/IL-15-induced
proinflammatory cytokine production, CD45ROþCD4þ
T cells were stimulated with IL-15 and TL1a in the
presence/absence of IL-12 or IL-18 (Figure 2). Removal of
IL-12 from the cytokine cocktail prevented IL-15/
TL1a-induced IFN-g production and reduced IL-15/TL1a-
induced TNF-a and IL-6 production (Figure 2a). However,
IL-12 was not required for TL1a/IL-15-mediated induction of
IL-5, IL-13, IL-22, and GM-CSF (Figure 2b). In contrast, the
ability of TL1a/IL-15 to induce all cytokines was markedly
reduced in the absence of IL-18 (Figure 2b). Collectively,
these results suggest that IL-18 is required for TL1a/IL-15-
driven proinflammatory cytokine production in CD45ROþ
CD4þ T cells.
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Figure 2 Interleukin-15 (IL-15) and tumor necrosis factor-like cytokine 1A (TL1a) induction of proinflammatory cytokines in CD45ROþCD4þ T cells
requires synergy with IL-18. Peripheral blood CD45ROþCD4þ T cells (1106 cells per ml, 200 ml per well) were cultured with IL-12 (2 ngml 1), IL-18
(50 ngml 1), IL-15 (25 ngml 1), andTL1a (100 ngml 1) as indicated, and cytokine levels were determined in culture supernatants at day 1 (interferon-g
(IFN-g)) or day 4 (other cytokines). (a) TL1a and IL-15 synergy in inducing IFN-g, IL-6, and TNF-a requires both IL-12 and IL-18. Results are the mean
(s.e.m.) of 4 (IFN-g) and 9 (IL-6 and TNF-a) biological replicates. (b) TL1a and IL-15 synergy in inducing GM-CSF, IL-5, IL-13, and IL-22 is IL-12
independent and IL-18 dependent. Results are the mean (s.e.m.) of 6 (IL-22) or 9 (other cytokines) biological replicates.
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IL-15 and TL1a synergize to induce IFN-c production in
IL-18Raþ CD45ROþCD4þ T cells
A subset of T cells expressing the C-type lectin membrane
glycoprotein and natural killer cell-associated marker CD161
were recently suggested to be the major TL1a-responsive
CD4þ T-cell subset in PB.12,13 Conversely, a subset of memory
CD4þ T cells expressing IL-18Rawas shown to be the primary
IFN-g-secreting population after stimulation with IL-15.10
We thus assessed the phenotype of cytokine-producing
CD45ROþCD4þ T cells after culture with the different
cytokine cocktails (Figure 3). In one day cultures containing
IL-12 and IL-18, IL-15 and TL1a alone or in combination
induced IFN-g production in a minor subset of PB CD45ROþ
CD4þ T cells that coexpressed IL-18Ra (Figure 3a), consistent
with the IL-18 dependency of this response (Figure 2a). While
the total number of CD4þ T cells and IL-18Raþ CD4þ T cells
in the wells did not change at this time point (Figure 3b),
addition of both IL-15 and TL1a to IL-12/IL-18 cultures
enhanced the proportion of IFN-g-producing IL-18Raþ
CD4þ T cells compared with either cytokine alone
(Figure 3a, c). Taken together, these results indicate that
TL1a and IL-15 in the presence of IL-12/IL-18 rapidly induce
IFN-g production in IL-18RaþCD45ROþCD4þ T cells and
that both cytokines synergize to promote this response.
TL1a and IL-15 synergize to induce proliferation of
IL-18Raþ CD4þ T cells
IL-18Raþ T cells were also the major proinflammatory cytokine
producers in 4 day cultures (Figure 3d).However, in contrast to
1 day cultures, by 4 days the total number of IL-18Raþ
T cells in IL-12/IL-18 cultures containing IL-15 or TL1a had
increased, and the numbers were further enhanced in IL-12/
IL-18 cultures containing both TL1a and IL-15 (Figure 3e).
To assess whether the increased number of IL-18Raþ cells in
4 day cultures could in part be explained by selective
proliferation of these cells, 5-bromodeoxyuridine (BrdU)
was added at the start of the culture and the percentage
and phenotype of BrdUþ cells were assessed after 4 days by
flow cytometry (Figure 3f, g). Only IL-18RaþCD4þ T cells
incorporated BrdU under all cytokine conditions (Figure 3f,
data not shown); however, the total percentage of CD4þ T cells
that incorporated BrdU was low, consistent with the
observation that total CD4þ T-cell counts did not differ
significantly between the culture conditions (Figure 3h). The
proportion of IL-18RaþCD4þ T cells that were BrdUþ
increased after the addition of TL1a or IL-15 to IL-12/IL-18
cultures, although the former did not reach statistical
significance (Figure 3g), and this was further increased
after the addition of both TL1a and IL-15 (Figure 3g).
Proliferation was not, however, required for cytokine-induced
IFN-g production (Figure 3i).
IL-18RaþCD45ROþCD4þ T cells express high level of the
TL1a receptor DR3 in cytokine cultures
Having identified IL-18Ra-expressing cells as the major
cytokine-responsive CD45ROþCD4þ T-cell subset, we next
assessed the expression of DR3 and CD161 on these cells
(Figure 4). DR3 expression was assessed by staining cells with
either a fluorescently labeled anti-DR3 Fab0 or a polyclonal
DR3 antibody (Supplementary Figure S4), and gave similar
results. The expression of IL-18Ra correlated with high
expression of DR3 under all cytokine culture conditions
(Figure 4a, b). While a large proportion of IL-18RaþDR3hi
CD4þ memory T cells also expressed CD161, both CD161þ
and CD161 IL-18RaþDR3hi cells produced IFN-g (Figure 4c).
Moreover, a subset of IL-18RaDR3lo cells expressed low
levels of CD161 and these cells failed to produce IFN-g
(Figure 4b). Overall, these data suggest that CD161 expression
is not a reliable marker for TL1a-responsive CD4þ T cells,
but that this property is restricted to a subset of CD45ROþ
IL-18RaþCD4þ T cells that express high levels of DR3.
TL1a inhibits IL-15-mediated induction of IL-10 in
CD45ROþCD4þ T cells
In addition to proinflammatory cytokines, we measured IL-10
levels in the CD45ROþCD4þ T-cell cultures (Figure 5).
In marked contrast to proinflammatory cytokine induction,
IL-15, but not TL1a, dose dependently induced IL-10 produc-
tion in IL-12/IL-18 cultures (Supplementary Figure S5 and
Figure 5a). IL-15 induction of IL-10 was dependent on the
presence of IL-12 but not IL-18 in the cultures (Figure 5a, b).
Further, rather than synergize with IL-15, addition of TL1a to
IL-12/IL-18/IL-15 cultures inhibited IL-15-induced IL-10
production (Figure 5a). The ability of TL1a to inhibit IL-15-
mediated induction of IL-10 was dependent on IL-18 and DR3
(Figure 5c, d). Staining for IL-10demonstrated that IL-15-induced
IL-10 production in both IL-18Raþ and IL-18RaCD4þ T cells
(Figure 5e), and that IL-10-producing cells were primarily
FoxP3 T cells (Figure 5f). Further TL1a inhibited IL-10
production in both IL-18Raþ and IL-18RaCD4þ T cells
(Figure 5e). Prior studies have suggested that functional IL-15Ra is
expressed by both IL-18Raþ and IL-18Ra memory CD4þ T
cells.10We thus assessed IL-15Ra expression on IL-18Raþ and IL-
18RaCD4þ T cells under the various culture conditions
(Figure 5g). IL-15Ra was expressed by IL-18Raþ and IL-
18RaCD4þ cells in both IL-12/IL-18 and IL-12/IL-18/TL1a
cultures. In contrast, IL-15Ra was not detected on either
population of cells in cultures containing IL-15, presumably as
a result of ligand-mediated receptor internalization,16 providing
further evidence that both IL-18Raþ and IL-18RaCD4þ cells
are responsive to IL-15. Collectively, these results indicate that
TL1a functions through IL-18RaþDR3þCD4þ T cells to
suppress IL-15-mediated induction of IL-10 in IL-18Raþ and
IL-18RaCD45ROþCD4þ T cells.
IL-18RaþDR3þ CD4þ Tcells are present at barrier surfaces
and display innate lymphocyte functionality
Most memory CD4þ T cells in the body are located at barrier
surfaces, where they are believed to have important roles in
maintaining tissue homeostasis and in protection against
invading pathogens.17 To determine whether tissue-resident
CD4þ T cells contained IL-18RaþDR3þCD4þ T cells, we
assessed IL-18Ra and DR3 expression on freshly isolated
CD4þ T cells isolated from human small intestine, colon, nasal
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polyps, and skin (Figure 6a, b). CD4þ T cells isolated from
healthy small intestine expressed low levels of DR3 (Supple-
mentary Figure S6); however, expression levels increased
after 2 days of culture in medium alone (Figure 6a and
Supplementary Figure S6), indicating that the enzyme cocktail
used to isolate these cells to some extent cleaved DR3. Consistent
with this possibility, the enzyme cocktail reduced DR3 expres-
sion on PB mononuclear cells (data not shown) and CD4þ T
cells that migrated out of undigested finely cut intestinal tissues
expressed DR3 at similar levels to those found after 2 days of
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Figure 3 Tumor necrosis factor (TNF)-like cytokine 1A (TL1a) and interleukin-15 (IL-15) synergize to induce proliferation of IL-18Raþ CD4þ T cells in
IL-12/IL-18 cultures. Peripheral blood CD45ROþCD4þ T cells (1 106 cellsml 1, 200 ml per well) were cultured in medium alone (control) or with IL-12
(2 ngml 1), IL-18 (50 ngml 1), IL-15 (25 ngml1), and TL1a (100 ngml1) as indicated. Representative flow cytometry plots depicting interferon-g
(IFN-g) expression by IL-18RaþCD4þ T cells (a), total number of live CD4þ cells (left) and total number of live CD4þ IL-18Raþ cells (right) (b) and
percent of IFN-gþ cells within the IL-18RaþCD4þ T cell population (c) after one day of culture. Results aremean (s.e.m.) from 4 biological replicates. (d)
Representative flow cytometry plots showing IFN-g-, TNF-a-, IL-6-, and granulocyte–macrophage colony-stimulating factor (GM-CSF)-expressing
CD4þ T cells (top row) and isotype controls (IFN-g, IL-6, and GM-CSF) and fluorescence minus one (FMO) (TNF-a) (lower row) as assessed by
intracellular cytokine staining after 4 daysof culturewith the indicatedcytokine cocktail. BrefeldinAwasadded to the cultures 4 hbeforeanalysis of TNF-a,
IL-6, and GM-CSF, whereas cultures for IFN-g analysis were left untreated. Numbers in quadrants represent the mean (s.e.m.) from 3 biological
replicates. (e) Number of IL-18RaþCD4þ Tcells at day 0 and after 4 days of culturewith the indicated cytokines. Results aremean (s.e.m.) of 6 biological
replicates. (fandg) IL-15 andTL1a induce selective proliferation of IL-18Raþ cells. 5-Bromodeoxyuridine (BrdU)was addedat the start of the culture and
incorporation assessed 4 days later by flow cytometry. (f) Representative flow cytometry plot and (g) percent BrdUþ cells within the IL-18Raþ CD4þ
population after incubation with the indicated cytokine cocktails or medium alone (control). Results are the mean (s.e.m.) of 6 biological replicates. (h)
Total number of live memory CD4þ T cells after 4 days of culture. Results are mean (s.e.m.) of 5 biological replicates. (i) Representative flow cytometry
plot assessing BrdU incorporation in IFN-gþCD4þ T cells after 4 days of culture with the indicated cytokine cocktail. Results are representative of 3
biological replicates.
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culture in the medium (Supplementary Figure S6). In contrast
to DR3, IL-18Ra expression was not affected by the digestion
procedure (data not shown). IL-18RaþDR3þCD4þ T cells
were present in all tissues, in particular within the small
intestine and colon, where they represented the majority of
CD4þ T cells (Figure 6b). Immunohistochemical analysis
demonstrated that DR3þ cells were scattered throughout the
small intestinal lamina propria (LP) (Figure 6c), and that most
of these cells coexpressed CD4 (Figure 6d). To determine
which tissue-derived CD4þ T cells could be induced to express
IFN-g following cytokine stimulation, cell suspensions from
the small intestine and nasal polyps (tissue samples that
contained the greatest number of cells) were cultured in
medium alone or with IL-12/IL-18/IL-15/TL1a and IFN-g
expression by CD4þ T cells assessed after 2 days by
intracellular staining (Figure 6e). Consistent with results
obtained with circulating CD45ROþCD4þ T cells, the
cytokine cocktail selectively induced IFN-g production in
nasal polyp or small intestinal-derived IL-18RaþDR3þCD4þ
T cells (Figure 6e). Collectively, these results indicate that
cytokine-responsive IL-18RaþDR3þCD4þ Tcells are present
in barrier tissues.
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TL1a and IL-15 synergize to promote proinflammatory
cytokines in tissue-resident IL-18RaþDR3þCD4þ T cells
To assess whether TL1a and IL-15 synergize to promote
cytokine production in tissue-resident IL-18RaþDR3þ CD4þ
T cells, we focused on small intestinal surgical samples, which
gave the numerically greatest yield of cells. LP mononuclear
cells (LPMCs) prepared from healthy human small intestine
were cultured with the various cytokine cocktails for 2 days.
Addition of cytokines did not have a significant impact on
CD4þ T-cell numbers during this time period (Figure 7a).
TL1a and IL-15 induced IFN-g production in LPMC cultures
containing IL-12/IL-18 and this was further enhanced after the
addition of both cytokines (Figure 7b). Similarly, TL1a and IL-
15 enhanced the proportion of IFN-g-expressing LP CD4þ
T cells in these cultures (Figure 7c). Addition of neutralizing
MHC-II antibody to the cultures had no impact on IFN-g
levels, indicating that cytokine-induced IFN-g production was
independent on cognate TCR–MHC-II interactions
(Supplementary Figure S7A). TL1a and IL-15 similarly
synergized to promote TNF-a, IL-6, GM-CSF, IL-5, and IL-
13 production in LPMC cultures in the presence of IL-12/IL-18
(Figure 7d). Intracellular cytokine staining confirmed that,
among LP CD4þ T cells, production of IFN-g (Figure 7e), IL-
6, GM-CSF, and TNF-awas restricted to IL-18RaþDR3þ cells
(Supplementary Figure S7B). However, as expected, other
cells including CD8þ T cells as well as CD3 cells produced
these cytokines in LPMC cultures (Supplementary Figure
S7C) and likely contributed to the overall cytokine levels
detected in LPMC culture supernatants. We were unable to
detect IL-5, IL-22, or IL-13 in any of these population by
intracellular flow cytometry. To determine directly whether
TL1a and IL-15 synergized to enhance cytokine production in
LP CD4þ T cells, CD4þ T cells were purified from LPMC
digestions by positive magnetic-activated cell sorting (purity
95%) and CD4þ and CD4 LPMC fractions were cultured for
2 days with the indicated cytokines (Figure 7e). The levels of
cytokines in the CD4þ and CD4- LPMC fractions were notably
lower compared with total LPMC (compare Figure 7d and e),
indicating that this purification procedure impacted on cellular
functionality, and we were unable to detect IL-13, IL-5, or GM-
CSF in either CD4þ or CD4 LPMC fractions (data not
shown). Nevertheless, TL1a and IL-15 displayed a significant
synergy, in the presence of IL-12/IL-18, in inducing IL-6, IFN-
g, and IL-22 in LP CD4þ T cells (Figure 7e). Collectively, these
results indicate that IL-15 and TL1a synergize to induce
proinflammatory cytokine production in tissue-resident
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IL-18RaþDR3þCD4þ T cells. Finally, as observed with PB
CD45ROþCD4þ T cells, addition of IL-15 to LPMC cultures
in the presence of IL-12/IL-18 induced IL-10 production in
LPMCs and this was inhibited by coincubation with TL1a
(Figure 7f). Further TL1a inhibited IL-15-induced IL-10
production in LP-derived CD4þ T cells as assessed by flow
cytometry analysis (Figure 7g, h).
IL-18RaþDR3þ T cells co-localize with IL-18 expressing
cells in the intestine of Crohn’s disease patients
IL-18, IL-15, IL-12, and TL1a expression is increased in a wide
array of autoimmune and chronic inflammatory diseases
including Crohn’s disease (CD)18–25 and have been implicated
in disease pathogenesis (for reviews see refs 26–28). We thus
assessed whether cytokine-responsive IL-18RaþDR3þCD4þ
T cells were present in the inflamed intestine of CD patients.
DR3þ cells were distributed diffusely throughout the small
intestine of CD patients and accumulated in large numbers
within lymphoid aggregates, many of which were B-cell-
containing lymphoid follicles (Figure 8a, data not shown).
Costaining confirmed that DR3þ cells within these aggregates
were CD4þ T cells and not B cells (Figure 8b, data not shown).
Consistent with this finding, many CD4þ T cells isolated from
the inflamed small intestine coexpressed DR3 and IL-18Ra
(Figure 8c). Given the requirement for IL-18 in cytokine-
induced CD4þ T-cell responses, we finally assessed IL-18
expression in the inflamed small intestine of CD patients and
determined whether IL-18 immune reactivity colocalized with
IL-18RaþDR3þCD4þ T cells (Figure 8d, e). IL-18 immune
reactivity was greater in the inflamed small intestine of CD
patients compared with healthy controls (Figure 8d). Further
in CD small intestine IL-18-expressing cells were primarily
localized within lymphoid aggregates in immediate proximity
to IL-18RaþDR3þCD4þ T cells (Figure 8e). Taken together,
these results suggest that lymphoid aggregates and lymphoid
follicles may serve as sites of cytokine-induced T-cell activation
in CD.
DISCUSSION
In the current study, we demonstrate potent synergy between
IL-15 and TL1a in inducing TCR-independent proinflamma-
tory cytokine production by human CD45ROþCD4þ T cells.
IL-15- and TL1a-induced proinflammatory cytokine produc-
tion was restricted to a subset of memory CD4þ T cells that
coexpressed IL-18Ra and DR3 and required the presence of
IL-18. IL-18RaþDR3þCD4þ T cells with similar functionality
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were present in a range of barrier tissues, most notably in the
intestine where they represented the majority of CD4þ T cells.
Thus, in addition to their well-recognized adaptive immune
functions, our results suggest that many tissue-resident
memory CD4þ T cells are capable of innate-like functionality
independent of cognate antigen recognition. Finally, IL-18Raþ
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DR3þCD4þ T cells localized together with IL-18-expressing
cells in lymphoid aggregates and lymphoid follicles in the
inflamed small intestine of CD patients, suggesting that these
structures may serve as potential sites of cytokine-induced
CD4þ T-cell activation in CD.
IL-12 and IL-18 induce limited IFN-g production in human
CD4þ T helper cells; however, the addition of either IL-15
or TL1a enhances this response.10,11 Furthermore, TL1a was
recently found in the presence of IL-12 and IL-18 to induce
production of multiple proinflammatory cytokines in PB
CD4þ T cells.13 Here we confirm and extend these findings,
demonstrating that both TL1a and IL-15 induce expression of
a wide range of cytokines, including IFN-g, IL-6, GM-CSF,
IL-5, IL-13, TNF-a, and IL-22 in CD45ROþCD4þ T cells and
show for the first time, as far as we are aware, a significant
synergy between TL1a and IL-15 in enhancing this response.
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While IL-18 was critically required for TL1a- and
IL-15-mediated induction of all inflammatory cytokines, IL-
12 was required for TL1a- and IL-15-mediated induction of
IFN-g, IL-6, and TNF-a, but not for TL1a- and IL-15-mediated
induction of IL-22- or the Th2-associated cytokines IL-13 and
IL-5 and GM-CSF. These results suggest that local levels of
IL-12 may determine whether TL1a and IL-15 skews innate
memory CD4þ T-cell responses toward a Th1- or Th2-domi-
nated response. Of note, transgenic expression of TL1a in
murine dendritic cells/macrophages or T cells leads to elevated
levels of IL-13 but not IFN-g, and development of
IL-13-mediated inflammation in the small intestine.29,30 While
RAG / mice transgenic for TL1a display enhanced levels of
IL-13 derived from TL1a-responsive ILC2s,31,32 our results
suggest that in a T-cell-competent setting, intestinal memory
CD4þ T cells may also contribute to this response.
Information on the phenotype of cytokine-responsive
CD4þ T cells is sparse. Sattler et al10 identified a subset of
circulating IL-18Raþ CD4þ T cells as the primary IFN-g-
producing cells after stimulation with IL-15/IL-12/IL-18,
whereas TL1a/IL-12/IL-18 has been shown to induce IFN-g
expression in a subset of memory CD4þ cells expressing
CD161.12,13 Our findings that TL1a and IL-15 induced pro-
inflammatory cytokine production was IL-18 dependent
suggested that both cytokines functioned primarily in IL-18Raþ
CD4þ Tcells. Consistentwith this possibility,we found that IL-15
and TL1a alone or in combination selectively induce proin-
flammatory cytokine expression in IL-18RaþCD4þ cells. We
found that PB IL-18Raþ but not IL-18Ra memory CD4þ T
cells in cytokine cultures expressed high levels of the TL1a
receptor, DR3. Further, while CD161 was coexpressed on a large
proportion of these cells, IL-18RaþDR3himemory T cells lacking
expression of CD161 produced IFN-g after cytokine stimulation,
demonstrating that CD161 is not a selective marker for IL-15- or
TL1a-responsive memory CD4þ T cells.
After 1 day of culture, IL-15 and TL1a synergized to induce
IFN-g production in IL-18RaþDR3þCD4þ T cells without
impacting on IL-18Raþ T-cell numbers. In contrast, increased
numbers of IL-18RaþCD4þ T cells were observed in 4 days of
culture, and BrdU incorporation studies demonstrated that
TL1a or IL-15 induced a selective proliferation of IL-18Raþ
CD4þ T cells that was further enhanced after the addition
of both cytokines. Thus, in addition to directly inducing
cytokine production in IL-18RaþCD4þ T cells, IL-15 and
TL1a synergize to promote IL-18RaþCD4þ T-cell prolifera-
tion. Proliferationwas not required for cytokine-induced IFN-g
production in IL-18RaþCD4þ T cells; however, enhanced
numbers of cytokine-responsive IL-18RaþCD4þ T cells in
cultures containing IL-15 and TL1a likely contributed to the
enhanced levels of proinflammatory cytokines observed in
these cultures.
In contrast to the IL-18-dependent proinflammatory cytokine
induction by IL-15, we found that IL-18 was not required for
IL-15-mediated induction of IL-10 inCD45ROþCD4þ T cells,
similar to previous findings in human natural killer cells.33
Consistent with these results, we found that both IL-18Raþ
and IL-18RaCD45ROþCD4þ T cells expressed IL-15Ra
and that IL-15 induced IL-10 production in both these
populations. Further, in direct contrast to the synergistic
activity of TL1a and IL-15 in driving proinflammatory cytokine
production, TL1a inhibited IL-15-mediated induction of IL-10
in both IL-18Raþ and IL-18RaCD45ROþCD4þ T cells.
While the underlying mechanism of TL1a-mediated inhibition
of IL-10 remains unclear, it was IL-18 and DR3 dependent,
demonstrating that inhibition requires signaling through
IL-18RaþDR3þCD4þ T cells, and indicating indirect inhibi-
tion via cell-bound and/or soluble factors generated by IL-
18Raþ T cells. Thus, TL1a and IL-15 display marked opposing
effects in regulating IL-10 production in CD45ROþCD4þ T
cells. The ability of TL1a to inhibit IL-10 production in
CD45ROþCD4þ T cells represents a novel proinflammatory
function for this cytokine.
Barrier tissues contain the largest population of memory
CD4þ T cells in the body, where they are believed to have key
roles in TCR-dependent immune surveillance after recognition
of foreign and self-antigen presented on local antigen-pre-
senting cells. Here we find that a large proportion of tissue-
resident memory CD4þ T cells, characterized by coexpression
of IL-18Ra and DR3, can be induced to express inflammatory
cytokines independently of cognate antigen recognition. We
further show that intestinal IL-18RaþDR3þ memory CD4þ
T cells are diffusely dispersed throughout the normal healthy
intestinal LP and are thus in immediate proximity to intestinal
macrophages and dendritic cells,34,35 which can serve as impor-
tant sources of IL-15, IL-18, IL-12, and TL1a,36–39 in particular
aftermicrobial and inflammatory insult.39–42 Collectively, these
findings suggest that IL-18RaþDR3þCD4þ T cells may con-
tribute to early innate non-cognate responses within these
tissues. Consistent with this possibility, non-cognate IL-18-
dependent cytokine production by CD4þ T cells was recently
suggested to contribute to the resolution of Salmonella infection
in mice.43
There is now considerable evidence that the TL1a/DR3 axis
has a central proinflammatory role in inflammatory bowel
disease.44 TL1a levels are elevated in the inflamed mucosa
of both CD and ulcerative colitis patients20,21 and single-
nucleotide polymorphisms in theTL1a gene are associated with
increased risk of inflammatory bowel disease.45,46 Further, in
animal models of colitis, neutralization of TL1a/DR3 activity
attenuates inflammation,29,47 whereas overexpression of TL1a
in the T-cell or myeloid compartment of mice leads to
spontaneous small intestinal inflammation.29,48 Our findings
that TL1a synergizes with IL-15 to enhance proinflammatory
cytokine production in PB and tissue-resident memory IL-
18RaþDR3þCD4þ T cells, combined with our observations
that IL-18RaþDR3þCD4þ T cells are present in large
numbers in the inflamed intestine of CD patients, suggest
that these cells are a potential TL1a target population in the
inflamed mucosa. Further studies will however be required to
determine the role of IL-18RaþDR3þCD4þ T cells, as well as
TL1a-dependent cytokine responses by these cells in inflam-
matory bowel disease pathogenesis.
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METHODS
Patient material. This study was carried out in accordance with the
Declaration of Helsinki. Healthy donor blood was obtained from
Rigshospitalet, Copenhagen, Denmark after informed consent. All
human tissue material was obtained through Skåne University
Hospital, Sweden except the intestinal cryosections inFigure 6c, d, and
Figure 8a, b that were obtained from Cambridge Bioscience
(Cambridge, UK). Healthy small intestinal tissue was obtained
from patients undergoing cystectomy with bladder reconstruction.
Inflamed small intestinal tissue was obtained from CD patients at
surgery or from biopsies at colonoscopy; healthy colon biopsies were
obtained from patients referred to colonoscopy because of bowel
discomfort, loose stool, or anemia that showed no endoscopic or
histologic signs of inflammation. Only CD patients and controls
without clinical signs of infection and not on immunosuppressive
medication were included in the study. Healthy skin samples were
obtained from patients undergoing surgery with full-thickness skin
grafting because of tumor excisions in the face. Patientswere not taking
immunosuppressivemedication and did not suffer from inflammatory
skin disease, such as atopic dermatitis or psoriasis. Finally, inflamed
nasal tissue was obtained from patients with nasal polyposis
undergoing routine polypectomy. All materials were obtained with
informed patient consent and in accordancewith local ethical approval
from the Regional Ethics committee.
Cell isolation
Isolation of PBmemory CD4þ T cells. CD4þ T cells were isolated from
whole blood by negative selection using ‘‘Rosette sep CD4þ T cell
enrichment cocktail’’ (StemCell Technologies, Vancouver, BC,
Canada) and memory CD4þ T cells were purified from the
CD4þ T cells by negative selection using the ‘‘Memory CD4þ T
Cell Isolation Kit’’ (Miltenyi Biotec, BergischGladbach, Germany) and
an autoMACS pro separator (Miltenyi Biotec). CD45ROþCD4þ
T-cell purity was 95–99%.
Isolation of intestinal LPMCs. Intestinal LPMCs were isolated from
surgical samples essentially as previously described.34,35 However,
after removal of epithelial cells, tissue was incubated in R-10 medium
(RPMI-1640, fetal calf serum (10%),HEPES (10mM), sodiumpyruvate
(1mM), b-mercaptoethanol (50 mM), penicillin (100Uml 1), and
gentamycin (50 mgml 1)) supplemented with 0.2mm-filtered col-
lagenase 1a (1mgml 1) and DNase I (10Uml 1) with magnetic
stirring at 37 1C for 60min. The cell suspension was then passed
through a 100 mm cell strainer, cells were washed, and then used for
experiments. For isolation of LP CD4þ cells, LPMCs were centrifuged
through a 40%/70% percoll gradient followed by positive selection by
magnetic-activated cell sorting using CD4 microbeads (Miltenyi
Biotec). For removal of epithelial cells from intestinal biopsies, tissue
fragments were first incubated in 20ml Hank’s balanced salt solution
containing EDTA (2mM), fetal calf serum (5%), HEPES (10mM), and
penicillin (100Uml 1) with magnetic stirring at 37 1C for 45min.
After incubation, the epithelial cells in suspension were removed by
aspiration and the remaining tissue was washed in R-10, and digested
as above.
Isolation of dermal cells. Skin samples were cut into 1 cm2 pieces and
placed into 25 cm2 tissue culture flasks (Sarstedt, Nu¨rnbrecht,
Germany) with 20ml Hank’s balanced salt solution containing EDTA
(2mM), fetal calf serum (5%), HEPES (10mM), and penicillin
(100Uml 1) for 20min with continuously shaking at 37 1C. The
epidermal layer was then cut from the tissue, and the remaining dermis
was cut into small pieces using surgical blades and put in R-10medium
supplemented with 0.2mm-filtered collagenase 1a (1mgml 1)
and DNase I (10Uml 1) with magnetic stirring at 37 1C for
60min. After digestion, the cell suspension was passed through
a 100mm cell strainer, and the collected cell pellet washed and used
in experiments.
Isolation of cells from nasal polyps. Isolation of cells from nasal polyps
was performed essentially as previously described.49 However, the
tissue was first incubated in 15ml Hank’s balanced salt solution
containing EDTA (2mM), fetal calf serum (5%), HEPES (10mM),
penicillin (100Uml 1), and DL-dithiothreitol (0.15mgml 1)
with magnetic stirring at 37 1C for 30min. After epithelial cell
removal, the remaining tissue was finely cut with surgical blades and
incubated in 10ml PBS containing collagenase D (0.5mgml 1),
DNase I (0.5mgml 1), and dispase II (3mgml 1) with magnetic
stirring at 37 1C for 60min. The resulting cell suspension was passed
through a 100mm cell strainer, cells were washed, and used for
experiments.
Cell culture. Cells (1 106 cellsml 1) were incubated in culture
medium (RPMI-1640, penicillin (100Uml 1), and human serum
(10%)) with the indicated cytokines in 96-well plates at 37 1C in 5%
CO2 for 1–4 days (PBCD45RO
þCD4þ T cells) or 2 days (cells derived
from intestine, skin, or nasal polyps). Cytokine levels in culture
supernatants were assessed by Bio-Plex Pro Human Cytokine
17-plex Assay or Bio-Plex Pro Human Th17 Cytokine IFN-g Set/Bio-
Plex Pro Human Th17 Cytokine IL-10 Set (Bio-Rad, Hercules, CA)
according to the manufacturer’s instructions using the Bio-Plex 200
System (Bio-Rad). For mixed lymphocyte reactions, peripheral
blood mononucleated cells from two donors were isolated using
Ficoll gradients and cultured (2 105 cells per donor, total volume
200 ml) in 96-well plates. Wells containing 4 105 cells from the
same donor were used as negative controls. [3H]thymidine
(Perkin-Elmer, Waltham, MA) was added to the cultures on day 3 at
1 mCi per well, and 18 h later, the cells were harvested using a filtermate
harvester (Perkin-Elmer) and analyzed using a Topcounter NXT
(Perkin-Elmer).
Generation of anti-DR3 Fab0. For the generation of antagonistic anti-
DR3 Fab0, mice were immunized with DR3 protein containing
extracellular domains only. Generated antibodies were screened for
their capacity to prevent TL1a binding to DR3-transfected cells
(HEK293 and CHO cells). The anti-DR3-Fab0 fragment was generated
by papain digestion. Anti-TNP IgG4 Fab0 was generated in house in a
similar manner and used as a control.
Generation of hDR3-transfected cells. The HEK293-EBNA
expression systemdescribed byDurocher et al.50 was used for transient
expression. Briefly, HEK293-6E cells were transiently transfected with
the suitable pTT5 vector, containing hDR3 with a truncated intra-
cellular death domain. An empty pTT5 vector was used as mock
control. Cells were transfected with 293Fectin (Invitrogen, Carlsbad,
CA) and standard 30 mg DNA/30ml culture (containing 106 cells per
ml).
Flow cytometry analysis. Flow cytometry analysis was performed
essentially as previously described.35 Before staining with relevant
antibodies, cells were incubated for 15min with 10% human serum.
For detection of DR3, cells were either (1) incubated with biotinylated
polyclonal DR3 antibody followed by incubation with biotinylated
anti-goat IgG and streptavidin-PE or (2) incubated with APC-DR3
Fab0. For detection of IL-10, T cells were stained with the APC-IL-10
secretion assay according to the manufacturer’s instructions (Miltenyi
Biotec), with an extended secretion period (1 h). Intracellular cytokine
and FoxP3 stainingwas performed using the BDCytofix/CytopermKit
(BD Biosciences, San Jose, CA) or Inside Stain Kit (Miltenyi Biotec)
according to the manufacturer’s instructions. Foxp3/Transcription
Factor Staining Buffer Set was used for FoxP3 staining according to the
manufacturer’s instruction (eBioscience, SanDiegoCA). For detection
of intracellular IL-6, TNFa, and GM-CSF (Figure 3c and
Supplementary Figure S7B), brefedin A (10 mgml 1) was added
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to the cell cultures 4 h before analysis. BrdU incorporationwas assessed
using the APC BrdU Flow Kit assay (Invitrogen) according to the
manufacturer’s instructions. Flow cytometrywas performed on anLSR
II flow cytometer (BD Biosciences) and data were analyzed with
FlowJo software (Tree Star, Ashland, OR).
Immunohistochemistry. For DR3 staining, 6 mm cryostat sections
were dried and fixed in ice-cold acetone. Nonspecific binding sites
were blocked with donkey serum (7%), human serum (3%), and non-
fat dry milk (3%). Sections were incubated with an in house-generated
mouse monoclonal antibody recognizing an epitope within the
cysteine-rich domain 3 in the DR3 extracellular domain, followed by a
biotinylated donkey anti-mouse secondary antibody (Jackson
ImmunoResearch, West Grove, PA). Antibody binding was detected
using peroxidase-conjugated avidin–biotin complex (VectorStain;
Vector Laboratories, Burlingame, CA) and indirect biotin-conjugated
tyramide signal amplification system (NEL700 from Perkin-Elmer)
visualized by diaminobenzidine (D5905; Sigma-Aldrich, St. Louise,
MO). All slides were scanned in a Nanozoomer digital slide scanner
(Hamamatsu, Hamamatsu City, Japan). Double immunofluorescence
staining for DR3 and CD4 were performed using the same DR3
antibody as above and a rabbit monoclonal anti-CD4 antibody (clone
SP35; Nordic BioSite, Stockholm, Sweden). Antibody binding was
visualized using tyramide signal amplification-Alexa 488 (DR3) and
goat anti-rabbit Alexa 594 (CD4) (Invitrogen). Slides were analyzed by
confocal microscopy using an FV10i confocal microscope (Olympus,
Tokyo, Japan). For IL-18 staining, 4 mm paraffin sections were stained
with polyclonal rabbit anti-IL-18 (Sigma; HPA 003980; dilution 1:100)
and mouse monoclonal anti-CD4 (Thermo Scientific, Waltham, MA;
4B12, 1:100) as primary antibodies using the EnVision Doublestain
System Kit (K5361; Dako, Glostrup, Denmark). For assessment of
immunoreactivity, slides were digitalized in an automated slide
scanner (ScanScope; Aperio Technologies, Vista, CA) and Visio-
morphDP image software (Visiopharm, Hoersholm, Denmark) was
used to quantify marker-specific chromogen, as described
previously.51
Statistical analysis. All single column comparisons were performed
using the paired Student’s t-test and all multiple column analyses
were performed using ‘‘repeated-measures ANOVA’’ followed by
‘‘Bonferroni’s multiple comparison test’’ (*Po0.05, **Po0.01, and
***Po0.001). Statistical analysis was performed using GraphPad
Prism software (GraphPad, La Jolla, CA).
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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